Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.64 |
| ▸ | BCR | P11274 | 12/20 | 0.64 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 3/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025205 | 0.91 | ABL1 (0.70) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5025931 | 0.91 | ABL1 (0.65) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL14286284 | 0.88 | ABL1 (0.68) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5025940 | 0.86 | ABL1 (0.64) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5029480 | 0.84 | ABL1 (0.73) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5023657 | 0.84 | ABL1 (0.80) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL716301 | 0.84 | ABL1 (0.71) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5972230 | 0.83 | ABL1 (0.60) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5023760 | 0.83 | ABL1 (0.58) | ABL1BCRKDRPDGFRBHDAC3 | |
| SCHEMBL5025920 | 0.83 | ABL1 (0.67) | ABL1BCRKDRPDGFRBHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-02-14 | — | — | US | claimed |
| EP-1711497-A1 | 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-10-18 | — | — | EP | claimed |
| WO-2005073225-A1 | 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-08-11 | — | — | WO | claimed |
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-02-14 | — | — | US | disclosed |
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-02-14 | — | — | US | disclosed |
| EP-1711497-A1 | 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005073225-A1 | 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039466-A1 | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | KIT, MAP3K2, RET | ABL1 22/4885BCR 349/4885KDR 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.